Enhancing engraftment of cord blood cells via insight into the biology of stem/progenitor cell function

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cord blood (CB) transplantation has been used over the last 24 years to treat patients with malignant and nonmalignant disorders. CB has its advantages and disadvantages compared with other sources of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) for transplantation. More knowledge of the cytokines and intracellular signaling molecules regulating HSCs and HPCs could be used to modulate these regulators for clinical benefit. This review provides information about the general field of CB transplantation and about studies from the author's laboratory that focus on regulation of HSCs and HPCs by CD26/DPPIV, SDF-1/CXCL12, the Rheb2-mTOR pathway, SIRT1, DEK, cyclin-dependent kinase inhibitors, and cytokines/growth factors. Cryopreservation of CB HSCs and HPCs is also briefly discussed.

Original languageEnglish
Pages (from-to)151-160
Number of pages10
JournalAnnals of the New York Academy of Sciences
Volume1266
Issue number1
DOIs
StatePublished - Aug 2012

Fingerprint

Hematopoietic Stem Cells
Stem cells
Fetal Blood
Blood Cells
Blood
Stem Cells
Cells
Cytokines
Cyclin-Dependent Kinases
Intercellular Signaling Peptides and Proteins
Transplantation
Molecules
Cord
Cryopreservation
Cell Transplantation

Keywords

  • Cord blood
  • Cytokines
  • Intracellular signals
  • Stem and progenitor cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

@article{92fd9450dc4b48b19d68a0528a01af3e,
title = "Enhancing engraftment of cord blood cells via insight into the biology of stem/progenitor cell function",
abstract = "Cord blood (CB) transplantation has been used over the last 24 years to treat patients with malignant and nonmalignant disorders. CB has its advantages and disadvantages compared with other sources of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) for transplantation. More knowledge of the cytokines and intracellular signaling molecules regulating HSCs and HPCs could be used to modulate these regulators for clinical benefit. This review provides information about the general field of CB transplantation and about studies from the author's laboratory that focus on regulation of HSCs and HPCs by CD26/DPPIV, SDF-1/CXCL12, the Rheb2-mTOR pathway, SIRT1, DEK, cyclin-dependent kinase inhibitors, and cytokines/growth factors. Cryopreservation of CB HSCs and HPCs is also briefly discussed.",
keywords = "Cord blood, Cytokines, Intracellular signals, Stem and progenitor cells",
author = "Hal Broxmeyer",
year = "2012",
month = "8",
doi = "10.1111/j.1749-6632.2012.06509.x",
language = "English",
volume = "1266",
pages = "151--160",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Enhancing engraftment of cord blood cells via insight into the biology of stem/progenitor cell function

AU - Broxmeyer, Hal

PY - 2012/8

Y1 - 2012/8

N2 - Cord blood (CB) transplantation has been used over the last 24 years to treat patients with malignant and nonmalignant disorders. CB has its advantages and disadvantages compared with other sources of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) for transplantation. More knowledge of the cytokines and intracellular signaling molecules regulating HSCs and HPCs could be used to modulate these regulators for clinical benefit. This review provides information about the general field of CB transplantation and about studies from the author's laboratory that focus on regulation of HSCs and HPCs by CD26/DPPIV, SDF-1/CXCL12, the Rheb2-mTOR pathway, SIRT1, DEK, cyclin-dependent kinase inhibitors, and cytokines/growth factors. Cryopreservation of CB HSCs and HPCs is also briefly discussed.

AB - Cord blood (CB) transplantation has been used over the last 24 years to treat patients with malignant and nonmalignant disorders. CB has its advantages and disadvantages compared with other sources of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) for transplantation. More knowledge of the cytokines and intracellular signaling molecules regulating HSCs and HPCs could be used to modulate these regulators for clinical benefit. This review provides information about the general field of CB transplantation and about studies from the author's laboratory that focus on regulation of HSCs and HPCs by CD26/DPPIV, SDF-1/CXCL12, the Rheb2-mTOR pathway, SIRT1, DEK, cyclin-dependent kinase inhibitors, and cytokines/growth factors. Cryopreservation of CB HSCs and HPCs is also briefly discussed.

KW - Cord blood

KW - Cytokines

KW - Intracellular signals

KW - Stem and progenitor cells

UR - http://www.scopus.com/inward/record.url?scp=84865365341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865365341&partnerID=8YFLogxK

U2 - 10.1111/j.1749-6632.2012.06509.x

DO - 10.1111/j.1749-6632.2012.06509.x

M3 - Article

VL - 1266

SP - 151

EP - 160

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

IS - 1

ER -